Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perfluorocarbon-based red blood cell substitutes

G P Biro1

  • 1Department of Physiology, Faculty of Medicine, University of Ottawa, Ontario, Canada.

Transfusion Medicine Reviews
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effects of hemodilution with Hemolink upon hemodynamics and blood flow distribution in anesthetized dogs.

Artificial cells, blood substitutes, and immobilization biotechnology·2002
Same author

The effects of hemodilution with Hemolink upon hemodynamics and blood flow distribution in anesthetized dogs.

Artificial cells, blood substitutes, and immobilization biotechnology·2002
Same author

A phase I study of oxidized raffinose cross-linked human hemoglobin.

Critical care medicine·2000
Same author

Haemodynamic response following a 10% topload infusion of HemolinkTM in conscious, anaesthetized and treated spontaneously hypertensive rats.

Transfusion medicine (Oxford, England)·2000
Same author

Systemic responses to SFHS-infusion in hemorrhaged dogs.

Artificial cells, blood substitutes, and immobilization biotechnology·1996
Same author

The role of amino groups in hemoglobin oxygen binding.

Advances in experimental medicine and biology·1996
Same journal

Evaluating the Safety of Tranexamic Acid in Cancer Surgery: Clinical Evidence and Biological Rationale.

Transfusion medicine reviews·2026
Same journal

Assessment of CTLA-4, LAG-3, and TIM-3 Expression in Pediatric Patients With β-Thalassemia Major and Their Association With Alloimmunization.

Transfusion medicine reviews·2026
Same journal

A Reply to "Beyond Implementation: The Need for Validation, Equity, and Real-World Accountability in AI for Transfusion Medicine".

Transfusion medicine reviews·2026
Same journal

Beyond Implementation: The Need for Validation, Equity, and Real-World Accountability in AI for Transfusion Medicine.

Transfusion medicine reviews·2026
Same journal

Trust Over Knowledge: Rethinking Donor Iron Supplementation Strategies in Modern Blood Services-Authors' reply.

Transfusion medicine reviews·2026
Same journal

The Effect of Stress Ball and Music on Anxiety, Distress, and Pain Levels During Platelet Apheresis Donation: Randomized Controlled Trial.

Transfusion medicine reviews·2026
See all related articles

Second-generation perfluorocarbon (PFC) emulsions show improved oxygen transport and biocompatibility, building on decades of research. These advanced PFCs hold promise for both transfusional and non-transfusional medical applications.

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Pharmacology

Background:

  • Perfluorocarbon (PFC) emulsions have been researched for decades as oxygen carriers.
  • Previous generations, like Fluosol-DA, demonstrated efficacy and relative safety.
  • Advances in physical chemistry and emulsion technology have driven the development of new PFC formulations.

Purpose of the Study:

  • To review the advancements in second-generation PFC emulsions since the last assessment 5 years prior.
  • To evaluate the progress in physicochemical principles applied to PFC and emulsifier selection.
  • To explore the potential transfusional and non-transfusional applications of these new PFC products.

Main Methods:

  • Review of recent research and development in PFC emulsion technology.

Related Experiment Videos

  • Analysis of physicochemical principles guiding PFC and emulsifier design.
  • Evaluation of clinical and preclinical data on second-generation PFCs, including Perflubron.

    • Main Results:

    • Second-generation PFC emulsions, exemplified by Perflubron, represent significant improvements over earlier formulations.
    • These new products exhibit enhanced oxygen-transporting capabilities and confirmed biocompatibility.
    • Multiple commercial entities are developing advanced PFC emulsions based on refined principles.

    Conclusions:

    • The latest generation of PFC emulsions demonstrates substantial progress in efficacy and safety.
    • PFC preparations are feasible for both transfusional (e.g., resuscitation, intraoperative use) and non-transfusional applications (e.g., diagnostic imaging, cancer therapy).
    • Further research is needed to establish the full potential and optimal deployment of these advanced PFCs in clinical settings.